Amneal Pharmaceuticals (AMRX) vs Axsome Therapeutics (AXSM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Amneal Pharmaceuticals (AMRX) has outperformed Axsome Therapeutics (AXSM) over the past year, gaining 76.7% versus a loss of 13.4%. Over five years, AMRX leads with a +396.9% price change compared with +250.4% for AXSM. Amneal Pharmaceuticals is the larger company by market cap ($7.36 billion vs $6.80 billion), about 1.1 times the size, while Axsome Therapeutics is growing revenue faster (+65.5% vs +8.0%).
On valuation, Amneal Pharmaceuticals trades at a lower forward P/E (17.1x vs 35.5x for Axsome Therapeutics). Amneal Pharmaceuticals converts more of its revenue into profit, with a net margin of 2.4% versus -28.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMRX | AXSM |
|---|---|---|
| Share price | $21.12 | $129.36 |
| Market cap | $7.36B | $6.80B |
| 1-day change | -1.26% | -4.66% |
| YTD return | +67.62% | -29.17% |
| 1-year return | +76.74% | -13.44% |
| 5-year return | +396.94% | +250.38% |
| P/E ratio (TTM) | 52.80 | — |
| Forward P/E | 17.13 | 35.47 |
| EPS (TTM) | $0.40 | $-3.03 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.02B | $638.50M |
| Revenue growth (YoY) | +8.05% | +65.55% |
| Net income (latest FY) | $72.06M | $-183.17M |
| Gross margin | 36.88% | 92.56% |
| Operating margin | 13.05% | -26.12% |
| Net margin | 2.39% | -28.69% |
| 52-week high | $22.13 | $260.19 |
| 52-week low | $11.71 | $123.00 |
| Distance from 52-week high | -4.54% | -50.28% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +15.01% | +104.56% |
| Average volume | 3.16M | 865.33K |
| Shares outstanding | 348.41M | 52.60M |
| Employees | 8,700 | 1,390 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AMRX has outperformed AXSM by 90.2 percentage points over the past year.
- Amneal Pharmaceuticals is more profitable, keeping 2.4 cents of every revenue dollar as net income versus -28.7 cents for Axsome Therapeutics.
- Axsome Therapeutics grew revenue faster in its latest fiscal year (+65.55% vs +8.05%).
About Amneal Pharmaceuticals
AMRX stock →Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE.
Health Care · Biotechnology: Pharmaceutical Preparations · 8,700 employees
About Axsome Therapeutics
AXSM stock →Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,390 employees
AMRX vs AXSM FAQ
Which is bigger, Amneal Pharmaceuticals or Axsome Therapeutics?
Amneal Pharmaceuticals (AMRX) is larger, with a market capitalization of $7.36B compared with $6.80B for Axsome Therapeutics (AXSM).
Which stock has performed better over the past year, AMRX or AXSM?
AMRX returned +76.74% over the past 12 months, compared with -13.44% for AXSM (price return, excluding dividends). Past performance does not predict future results.
Are Amneal Pharmaceuticals and Axsome Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.